These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11762182)

  • 1. [Advanced glycosylation in diabetes mellitus. Occurrence of late complications].
    Esteves MC; Gonçalves AM; Caldeira JL
    Acta Med Port; 2001; 14(4):409-12. PubMed ID: 11762182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced nonenzymatic glycation endproducts (AGE): their relevance to aging and the pathogenesis of late diabetic complications.
    Sensi M; Pricci F; Andreani D; Di Mario U
    Diabetes Res; 1991 Jan; 16(1):1-9. PubMed ID: 1818791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microvascular basement membranes in diabetes mellitus.
    Tsilibary EC
    J Pathol; 2003 Jul; 200(4):537-46. PubMed ID: 12845621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-enzymatic glycation of proteins: a cause for complications in diabetes.
    Nawale RB; Mourya VK; Bhise SB
    Indian J Biochem Biophys; 2006 Dec; 43(6):337-44. PubMed ID: 17285797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes.
    Gardiner TA; Anderson HR; Stitt AW
    J Pathol; 2003 Oct; 201(2):328-33. PubMed ID: 14517851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of CML-modified proteins in hemofiltrate of diabetic patients by proteome analysis.
    Schmitt S; Linder M; Ständker L; Hammes HP; Preissner KT
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):26-34. PubMed ID: 17926233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background.
    Kalousová M; Zima T; Tesar V; Dusilová-Sulková S; Skrha J
    Mutat Res; 2005 Nov; 579(1-2):37-46. PubMed ID: 16084533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoxidation: the menace of diabetes and aging.
    Vlassara H; Palace MR
    Mt Sinai J Med; 2003 Sep; 70(4):232-41. PubMed ID: 12968196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of extracellular matrix glycosylation on proliferation and apoptosis of human dermal fibroblasts via the receptor for advanced glycosylated end products.
    Niu Y; Xie T; Ge K; Lin Y; Lu S
    Am J Dermatopathol; 2008 Aug; 30(4):344-51. PubMed ID: 18645306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
    Jandeleit-Dahm K; Watson A; Soro-Paavonen A
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
    Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?
    Kanková K
    Proc Nutr Soc; 2008 Feb; 67(1):60-74. PubMed ID: 18234133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing.
    Yan SF; Yan SD; Herold K; Ramsamy R; Schmidt AM
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):511-24, viii. PubMed ID: 16959583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced glycation end products and diabetic foot disease.
    Huijberts MS; Schaper NC; Schalkwijk CG
    Diabetes Metab Res Rev; 2008; 24 Suppl 1():S19-24. PubMed ID: 18442180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.
    Brownlee M; Cerami A; Vlassara H
    N Engl J Med; 1988 May; 318(20):1315-21. PubMed ID: 3283558
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.
    Yonekura H; Yamamoto Y; Sakurai S; Petrova RG; Abedin MJ; Li H; Yasui K; Takeuchi M; Makita Z; Takasawa S; Okamoto H; Watanabe T; Yamamoto H
    Biochem J; 2003 Mar; 370(Pt 3):1097-109. PubMed ID: 12495433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of advanced glycation endproducts in saliva from patients with diabetes mellitus.
    Yoon MS; Jankowski V; Montag S; Zidek W; Henning L; Schlüter H; Tepel M; Jankowski J
    Biochem Biophys Res Commun; 2004 Oct; 323(2):377-81. PubMed ID: 15369762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced glycation endproducts: what is their relevance to diabetic complications?
    Ahmed N; Thornalley PJ
    Diabetes Obes Metab; 2007 May; 9(3):233-45. PubMed ID: 17391149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.